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Objectives This study sought to assess the impact of baseline heart failure (HF) burden on survival with primary implantable
cardioverter-defibrillator (ICD) among Medicare recipients.
Background Survival after primary ICD implantation may differ between trial and Medicare populations.
Methods Linking data from the CMS (Centers for Medicare and Medicaid Services) ICD registry and the Medicare files
(2005 to 2009), we identified primary ICD recipients age 66 years with ejection fraction 35%. Number of
previous HF hospitalizations (prev-HF-hosp) and length of hospitalization prior to implantation were used to de-
fine HF burden. Crude all-cause mortality was estimated. Adjusted hazard ratios (HR) were derived from Cox
models.
Results Of 66,974 ICD recipients (73% men, 88% white, mean age 75 years), 11,876 died (average follow-up  1.4
years), with 3-year mortality of 31%. Among patients with no prev-HF-hosp, 3-year mortality was 27% compared
with 63% in those with 3 prev-HF-hosp (adjusted HR: 1.8). Among patients with same-day implantation, 3-year
mortality was 25% compared with 53% in those with 1-week hospitalization days prior to implantation (ad-
justed HR: 1.9). Mortality at 3-year follow-up among the 31,685 ICD recipients with no prev-HF-hosp and same-
day implantation (low HF burden) was similar to that in trials (22%).
Conclusions Nearly one-third of Medicare ICD recipients died within 3 years, reflecting a population with more advanced age
and disease than seen in trial populations for primary prevention ICD. Nearly one-half of Medicare recipients had
a low HF burden and had a survival similar to trial ICD recipients. Future research is warranted to understand the
effectiveness of primary ICD implantation among Medicare beneficiaries with heavy HF burdens. (J Am Coll
Cardiol 2013;61:2142–50) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.043Several landmark trials have demonstrated the efficacy of
implantable cardioverter-defibrillators (ICD) in systolic heart
failure (HF) (1–3). As a result, the Centers for Medicare and
Medicaid Services (CMS) issued a national coverage determi-
nation in 2005 that expanded the ICD indication to include
primary prevention of sudden cardiac death (SCD) among
Medicare beneficiaries with previous myocardial infarction or
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extrapolated to project that ICD may be indicated to prolong
survival for as many as 800,000 additional HF patients, most of
whom are over 65 years old (5).
The demographics of patients currently receiving ICD
indicate that they are older with a higher prevalence of
noncardiac comorbidities than their counterparts who are
enrolled in the landmark clinical trials (6). The survival benefit
of ICD is likely to attenuate with age (7–9), because increasing
age has been associated with a decreased risk of SCD among
HF populations (7,8) and noncardiac death is more common
in older ICD recipients (10). The survival benefit of ICD also
diminishes among patients with noncardiac comorbidities,
such as chronic kidney disease (9,11,12).
The efficacy of ICD implantation for primary prevention
(primary ICD) has been demonstrated among outpatient
trial participants with stable mild-moderate HF symptoms,
which have informed long-term cost-effectiveness estimates
(1,13,14). It is not known how these benefits might trans-
late to older patients with differing HF burdens, as reflected
by multiple previous HF hospitalizations or prolonged
current hospitalization for acute decompensation of chronic
HF. In this study, we aimed to: 1) describe long-term
survival with primary ICD in the Medicare population; and
2) evaluate the impact of HF and comorbidity burden on
survival with ICD, using the number of previous HF
hospitalizations and the length of hospitalization prior to
ICD implantation as proxies for chronic and acute HF
burden, respectively.
Methods
Data sources. We conducted a retrospective cohort study
using the CMS-ICD registry and MedPAR (Medicare
Provider Analysis and Review) files from January 1, 2005,
through December 31, 2009.
CMS-ICD REGISTRY. The CMS-ICD registry is a subset of
he ACC-NCDR (American College of Cardiology–
ational Cardiovascular Data Registry) ICD registry,
hich is the sole repository for ICD implantation data for
edicare beneficiaries (15–19). The registry was developed
hrough a partnership of the Heart Rhythm Society and the
merican College of Cardiology Foundation, using the
xpertise of the NCDR. The data are entered by hospital
ersonnel and are only included in the analytic file if
ospitals achieve certain completeness on specific data
lements (20). In addition, a subset of hospitals is randomly
elected for quality control review to evaluate data accuracy.
urrently, over 400,000 patients are included in the CMS-
CD registry, which contains 37 of 170 data elements that
he ACC-NCDR collects. These 37 elements include a
atient’s identifying information, history and clinical charac-
eristics, medications, facility information, provider informa-
ion, ICD indications, device information, and in-hospital
omplications.MEDPAR FILE. The MedPAR
file contains data from claims for
services provided to fee-for-
service beneficiaries admitted to
Medicare-certified inpatient
hospitals. It includes informa-
tion on beneficiary demograph-
ics, diagnoses, procedures, and
health resource use from hospi-
tals or skilled nursing facilities,
as well as detailed data on ac-
commodation and departmen-
tal charges, days of care, and
entitlement.
We linked the ICD registry to
MedPAR files by 4 nonunique
identifiers: sex, date of birth, ad-
mission date for ICD implanta-
tion, and provider identification number, similarly to previ-
ously described methods (21,22). We validated this linkage
by comparing it with a linkage using a personal identifier
(social security number cross-linked to beneficiary identifi-
cation number) among the subset of the data that had this
identifier. We found that our linkage method had 95%
specificity, 98% sensitivity, and 98% positive predictive
value compared with the linkage method using personal
identifiers.
Study population. The study population consisted of
Medicare fee-for-service beneficiaries who had a reduced
(35%) EF and received an ICD for the primary
prevention of SCD (Table 1). Patients who had a history
of cardiac arrest or sustained ventricular tachycardia were
excluded. We also required patients to be eligible for
Medicare for at least 1 year prior to the index procedure
and to be at least 66 years of age at the time of
implantation. We censored patients in the analyses at the
earliest occurrence of the following: death; or the end of
the study period.
Outcome. The study outcome was all-cause mortality. The
date of death was obtained from the MedPAR file.
Measures of acute and chronic HF burden and sub-
groups. We used the number of previous HF hospitaliza-
tions and the length of hospitalization prior to ICD im-
plantation as indicators of chronic and acute HF burden.
We followed a previously validated algorithm with a positive
predictive value of 94% to identify HF hospitalizations
within 1 year prior to ICD implantation from MedPAR
data (23), and then categorized the number of previous HF
hospitalizations into 4 levels (Table 2). We also classified
the interval from admission to ICD implantation into 4
levels (Table 3). Patients who had no previous HF hospi-
talization and received ICD on the admission date were
considered to have low burden of HF.
Statistical analysis. Baseline characteristics of the overall
study population and each subgroup were characterized by
Abbreviations
and Acronyms
CMS  Centers for
Medicare and Medicaid
Services
CRT  cardiac
resynchronization therapy
EF  ejection fraction
HF  heart failure
HR  hazard ratio(s)
ICD  implantable
cardioverter-defibrillator(s)
NYHA  New York Heart
Association
SCD  sudden cardiac
deathpercentages for categorical variables and using medians and
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continuous variables.
We graphed cumulative mortality over time using
Kaplan-Meier estimates for the entire study population and
for each subgroup. Differences among subgroups were
tested using log-rank tests. We used proportional hazards
regression models to derive crude, demographic (age, sex,
and race), and multivariable-adjusted hazard ratios (HR)
among the subgroups. We attempted to account for the
impact of other measures of HF severity (such as HF
duration and New York Heart Association [NYHA] class)
and of comorbidities (such as coronary artery disease,
unsustained ventricular tachycardia, nondilated cardiomy-
opathy, cerebrovascular disease, diabetes, chronic kidney
disease, chronic obstructive pulmonary disease, osteopo-
rosis, mental disorders, metastatic cancer) on post-
implantation mortality in the multivariable-adjusted model
(see notes for Tables 2 and 3 for the complete list of
Main Characteristics and OutcomesAmong Medica e Beneficiaries ReceivingPrimary ICD Implantations (n  66,974)
Table 1
Main Chara teristics and Outcomes
Among Medicare Beneficiaries Receiving
Primary ICD Implantations (n  66,974)
Characteristics
Median age, yrs 75 (71–80)
Male 48,853 (73)
White 58,916 (88)
Median EF, % 25 (20–30)
HF duration
New HF 7,965 (12)
0–3 months 9,389 (14)
3–9 months 8,652 (13)
9 months 40,175 (61)
Missing 793
NYHA functional class
I 3,926 (6)
II 20,647 (31)
III 38,667 (58)
IV 3,384 (5)
Missing 350
QRS interval 120 ms 42,269 (63)
Ischemic cause HF 53,232 (79)
1 previous hospitalization for any cause 18,752 (28)
5 previous hospitalizations for any cause 2,624 (4)
Cardiac resynchronization
therapy–defibrillators
32,201 (48)
Outcomes
Death 11,876
In-hospital death 327
In-hospital death risk, % 0.49 (0.45–0.55)
Average follow-up, yrs (days–yrs) 1.4 (0–4)
Mortality rate, per 1,000 person-yrs 128
1-yr mortality risk, % 12 (12–13)
2-yr mortality risk, % 22 (22–23)
3-yr mortality risk, % 31 (30–32)
Values aremedian (interquartile range), n (%), n, or hazard ratio (HR) (95% confidence interval [CI]).
EF  ejection fraction; HF  heart failure; ICD  implantable cardioverter-defibrillator(s);
NYHA  New York Heart Association.ovariates in the model). aAll analyses were conducted using SAS for Windows
release 9.2, SAS Institute Inc., Cary, North Carolina). The
tudy was approved by the institutional review board of
righam and Women’s Hospital.
esults
haracteristics and survival of overall Medicare patients
ith ICD. The final study cohort consisted of 66,974
edicare HF patients who underwent ICD implantation
or primary prevention of SCD (see the Online Appendix
or the description of the final study patients). The median
ge was 75 years and the majority were men (73%) and
hite (88%) (Table 1). More than one-half of the patients
61%) had known HF for more than 9 months, with 79%
aving HF due to an ischemic cause. The median EF was
5%. Over one-quarter (28%) of the patients were hospi-
alized at least once for any cause within 1 year prior to
mplantation, among whom 14% had more than 5 hospital-
zations. During the average follow-up of 1.4 years, 11,876
atients died. One-, 2-, and 3-year mortality rates after ICD
mplantation were 12%, 22%, and 31%, respectively (Table 1).
hronic HF burden: number of previous HF hospital-
zations. At least 1 previous hospitalization for HF had
ccurred in the year preceding ICD implantation for 14,011
atients (21%). Of these, 27% had 2 or more hospitaliza-
ions attributed to HF (Table 2). A higher number of
revious HF hospitalizations were associated with lower
F: 31% had EF 20% among patients with no previous
F hospitalization versus 48% among patients with 3 or
ore previous HF hospitalizations). Previous HF hospital-
zation was also associated with higher NYHA class at time
f implantation: 59% of patients with no previous HF
ospitalization had NYHA class III/IV symptoms at im-
lantation compared with 84% among patients with 3 or
ore previous HF hospitalizations. Chronic HF burden
as also associated with more frequent comorbidities, as
eflected by the number of previous all-cause hospitaliza-
ions and the Charlson comorbidity score (Table 2).
ortality by the number of previous HF hospitalizations.
fter ICD placement, mortality at 3 years increased from
7% in patients without previous HF hospitalization to 63%
n those with 3 or more previous HF hospitalizations (Table 2,
ig. 1). Among patients who had more than 3 previous HF
ospitalizations, more than one-half died within 2 years of
mplantation (Fig. 1). Compared with patients without a
revious hospitalization, the crude HR for mortality
anged from 1.7 for patients with 1 previous HF hospi-
alization to 3.4 for patients with 3 or more previous HF
ospitalizations. The pattern of HR across levels of
hronic HF burden remained similar after adjusting for
emographics. The impact of number of hospitalizations
n all-cause mortality suggests that the number of hos-
italizations may serve as a surrogate for HF severity and
omorbidities, because its effect diminished substantially
fter adjusting for these variables in multivariable analy-
comorb
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May 28, 2013:2142–50 ICD and Heart Failure Burdenses (Table 2). Although close to one-half (48%) (Table 1)
of the patients received a CRT-defibrillator device, the
impact of the number of previous HF hospitalization on
post-implantation mortality did not vary by device type
(data available upon request).
Acute HF burden: number of days from admission to
ICD implantation. Of 27,398 patients who had at least 1
hospital day between the admission day and ICD implan-
tation, 62% had been hospitalized for 2 to 7 days prior to the
procedure. Similar to the impact of the number of previous
Characteristics and Outcomes by the Number oTable 2 Characteristics and Outcomes by th
0 Hospitalizations
n  52,963 (79)
1
n
Characteristics
Age, yrs 75 (71–80)
70 13,005 (25)
80 14,025 (26)
Male 39,620 (75)
White 47,332 (89)
EF, % 25 (20–30)
20% 16,418 (31)
HF duration 52,705
New HF 7,965 (15)
0–3 months 7,297 (14)
3–9 months 6,317 (12)
9 months 31,126 (59)
NYHA functional class 52,663
I 3,617 (7)
II 17,597 (33)
III 29,239 (56)
IV 2,210 (4)
QRS interval 120 ms 32,949 (62)
Ischemic cause HF 42,168 (80)
Unsustained VT 12,382 (23)
Previous hospitalization
for any cause
0.6 1
5 506 1
LOS of implantation 3.9 5.2
Charlson score* 0.6 1.2
Outcomes
Death 8,135
Average follow-up, yrs
(range: days–yrs)
1.4 (0–4)
Median survival, yrs †
1-yr mortality risk, % 10 (10–11)
2-yr mortality risk, % 19 (19–20)
3-yr mortality risk, % 27 (27–28)
HR for death —
Age-, sex-, race-adjusted HR —
Multivariable adjusted HR§ —
Values are median (IQR), n (%), mean  SD, or HR (95% CI). Dashes
(myocardial infarction and heart failure). †The marked survival times a
survival time. §Adjusted for: age; sex; race; year of implantation; de
discharge; EF; ischemic HF; QRS interval duration; NYHA class; HF
cardiomyopathy, cerebrovascular disease, diabetes, chronic kidney dis
depression, mania, anxiety, psychotic disorder, delirium, or metastati
(CABG)/percutaneous coronary intervention (PCI) in 90 days; previous
hospitalizations for any cause, MI, or other cardiac disease; Charlson
LOS  length of stay; other abbreviations as in Table 1.HF hospitalizations, a longer duration from admission toICD implantation was associated with lower EF, higher
NYHA class, and higher comorbidity burden. It was also
associated with greater proportion of HF of ischemic origin
(79% in the same-day implantation patients versus 83% in
those who hospitalized for 8 or more days before implan-
tation) (Table 3).
Mortality by the number of days from admission to ICD
implantation. Mortality at 3 years was more than twice as
high, from 25% in patients with same-day implantation to
53% in the patients hospitalized for 8 or more days before
ious HF Hospitalizationsmber of Previous HF Hospitalizations
italization
,247 (15)
2 Hospitalizations
n  2,501 (4)
>3 Hospitalizations
n  1,263 (1)
1–80) 76 (71–81) 76 (71–80)
7 (23) 564 (23) 309 (24)
6 (29) 733 (29) 346 (27)
6 (67) 1,566 (63) 761 (60)
2 (85) 1,968 (79) 934 (74)
0–30) 25 (20–30) 23 (20–30)
6 (43) 1,075 (43) 610 (48)
816 2,422 1,238
(0) 0 (0) 0 (0)
7 (16) 348 (14) 157 (12)
1 (18) 398 (16) 166 (13)
8 (66) 1,676 (69) 915 (74)
,211 2,489 1,261
3 (2) 44 (2) 12 (1)
6 (23) 474 (19) 189 (15)
4 (67) 1,716 (69) 882 (70)
8 (7) 255 (10) 178 (14)
7 (67) 1,651 (66) 852 (67)
5 (78) 2,020 (81) 1,049 (83)
3 (22) 590 (24) 309 (24)
 1.3 3.2 1.4 5.5 2.6
 5 402 16 720 57
 5.5 5 6 5.9 6.2
 1.6 2.5 1.7 3.1 1.8
449 769 523
–4) 1.3 (0–4) 1.1 (0–4)
† 3 (2.9–3.4) 2.9 (1.7–2.1)
6–18) 24 (23–26) 33 (30–36)
9–31) 37 (35–40) 51 (48–55)
8–43) 52 (46–57) 63 (57–68)‡
.6–1.7) 2.2 (2.1–2.4) 3.4 (3.2–3.8)
.6–1.7) 2.2 (2.0–2.3) 3.3 (3.0–3.6)
.1–1.2) 1.3 (1.2–1.5) 1.8 (1.6–2.0)
te that data were unavailable. *Without counting cardiac conditions
ored observations. ‡Follow-up was not long enough to observe median
e; time from admission to implantation; time from implantation to
n; presence of unsustained ventricular tachycardia (VT), nondilated
ronic obstructive pulmonary disease (COPD), osteoporosis, dementia,
r; myocardial infarction (MI) in 40 days; coronary artery bypass graft
u vaccine or pneumococcal vaccine; pacemaker; number of previous
idity score without counting MI and HF.f Preve Nu
Hosp
 10
76 (7
2,35
3,01
6,90
8,68
25 (2
4,40
9,
0
1,58
1,77
6,45
10
25
2,38
6,82
74
6,81
7,99
2,27
2
498
4.2
1.8
2,
1.3 (0
17 (1
30 (2
40 (3
1.7 (1
1.6 (1
1.2 (1
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re cens
vice typ
duratio
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use of flimplantation (Table 3, Fig. 2). Among patients who had
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ICD and Heart Failure Burden May 28, 2013:2142–50more than 8 hospitalization days before implantation, more
than one-half died by 3 years (Fig. 2). Compared with the
same-day implantation group, the crude HR for mortality
ranged from 1.4 in the same-day implantation group to 3.4
in the 8-or-more-days group. The pattern of elevated HR
remained similar after adjusting for demographics. After
adjusting for HF severity and comorbidities, the impact of
the hospitalization duration on mortality was attenuated,
indicating that duration of hospitalization, as with number
of HF hospitalizations, likely serves as a surrogate for overall
Characteristics and Outcomes by the Number oImpl ntationTable 3 Characteristics and Outcomes by thImplantation
0 Days
n  39,576 (59)
Characteristics
Age, yrs 75 (70–80)
70 10,005 (25)
80 9,982 (25)
Male 29,145 (74)
White 35,815 (91)
EF, % 25 (20–30)
20% 11,845 (30)
HF duration 39,071
New HF 4,919 (13)
0–3 months 4,007 (10)
3–9 months 5,533 (14)
9 months 24,612 (63)
NYHA functional class 39,398
I 2,555 (6)
II 13,510 (34)
III 22,286 (57)
IV 1,047 (3)
QRS interval 120 ms 25,363 (64)
Ischemic cause HF 31,111 (79)
Unsustained VT 6,384 (16)
Previous hospitalization for
any cause
0.9 1.3
5 919 2
Time from implantation to
discharge, days
1.4 1.7
Charlson score* 0.8 1.3
Outcomes
Death 5,245
Average follow-up, yrs
(range: days–yrs)
1.5 (0–4)
Median survival, yrs †
1-yr mortality risk, % 8 (8–8)
2-yr mortality risk, % 16 (16–17)
3-yr mortality risk, % 25 (24–25)
HR for death —
Age-, sex-, race-adjusted HR —
Multivariable adjusted HR‡ —
Values are median (IQR), n (%), or HR (95% CI). Dashes indicate data
not long enough to observe median survival time. ‡Adjusted for: ag
discharge; EF; ischemic HF; QRS interval duration; NYHA class; HF durat
disease, diabetes, chronic kidney disease, COPD, osteoporosis, deme
cancer; MI in 40 days; CABG/PCI in 90 days; previous use of flu vaccine
for any cause, HF, MI, or other cardiac disease; Charlson comorbidity
Abbreviations as in Tables 1 and 2.disease severity (Table 3). The impact of the hospitalizationduration on post-implantation mortality was also the same
between patients who received CRT-defibrillator and sim-
ple ICD (data available upon request).
A subgroup with low HF burden. Accumulating acute and
chronic HF burden is associated with escalating mortality risk.
Conversely, patients who had no HF hospitalization in the
year before ICD implantation and who received the device on
the admission day (47%, n  31,685) had the lowest risk of
mortality (Table 4). In fact, these patients without a high
burden of HF had similar mortality after ICD implantation as
s From Admission to ICDmber of Day From Admission to ICD
1 Day
5,636 (8)
2–7 Days
n  16,959 (25)
>8 Days
n  4,803 (6)
6 (71–80) 76 (71–81) 76 (71–81)
,260 (22) 3,877 (23) 1,093 (23)
,553 (28) 5,151 (30) 1,434 (30)
,269 (76) 12,027 (71) 3,412 (71)
,023 (89) 14,198 (84) 3,880 (81)
5 (20–30) 25 (20–30) 25 (20–30)
,034 (36) 6,743 (40) 2,156 (45)
5,570 16,766 4,774
748 (13) 1,898 (11) 400 (8)
793 (14) 3,379 (20) 1,210 (25)
658 (12) 1,928 (12) 533 (11)
,371 (61) 9,561 (57) 2,631 (55)
5,605 16,852 4,769
348 (6) 866 (5) 157 (3)
,662 (30) 4,449 (26) 1,026 (21)
,321 (59) 10,089 (60) 2,971 (62)
274 (5) 1,448 (9) 615 (13)
,752 (67) 10,365 (61) 2,789 (58)
,452 (79) 13,662 (81) 4,007 (83)
,436 (26) 5,578 (33) 2,156 (45)
.1 1.5 1.1 1.6 1.4 1.8
02 4 738 4 267 6
.1 2.7 2.8 3.2 4.4 5
1 1.4 1.1 1.6 1.3 1.7
972 3,999 1,660
(0–4) 1.3 (0–4) 1.2 (0–4)
† 3.8 (3.8–3.8) 2.7 (2.6–3.3)
(11–13) 18 (18–19) 29 (28–31)
(21–23) 30 (29–31) 43 (41–44)
(29–35) 41 (39–42) 53 (50–57)
(1.3–1.5) 2.1 (2.0–2.2) 3.4 (3.2–3.6)
(1.3–1.5) 2.0 (1.9–2.1) 3.2 (3.1–3.4)
(1.0–1.2) 1.4 (1.4–1.5) 1.9 (1.8–2.0)
ot available. *Without cardiac conditions: MI and HF. †Follow-up was
race; year of implantation; device type; time from implantation to
sence of unsustained VT, nondilated cardiomyopathy, cerebrovascular
pression, mania, anxiety, psychotic disorder, delirium, or metastatic
mococcal vaccine or pacemaker; number of previous hospitalizations
ithout counting MI and HF.f Daye Nu
n 
7
1
1
4
5
2
2
3
1
3
3
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May 28, 2013:2142–50 ICD and Heart Failure Burdenmortality was seen for primary ICD recipients with both
chronic and acute burdens of HF at the time of implantation
(n  6,120, 3-year mortality: 50% to 69%) (Table 4).
iscussion
e assessed mortality after ICD implantation in a large
opulation of Medicare beneficiaries using a national ICD
egistry linked to Medicare inpatient claims data. Approx-
mately 1 in 3 Medicare patients died within 3 years of
mplantation in our study. We observed higher mortality
mong patients with a higher number of previous HF
ospitalizations (measure of chronic HF burden) and a
onger duration between admission and ICD implantation
measure of acute HF burden). Both measures may be
urrogates not only for HF severity but also for other
omorbidities, and they have additive effects on post-ICD
ortality. Although our analyses did not include a compar-
son group of non-ICD recipients and could not estimate
he relative effect of ICD in these subgroups, they provided
nsights on the subpopulations that are less likely to expe-
ience a competing risk of mortality that cannot be pre-
ented by ICD therapy. Specifically, we observed nearly
ne-half of the Medicare ICD recipients had low burden of
Figure 1 Kaplan-Meier Cumulative Crude Mortality by the Num
After implantable cardioverter-defibrillator (ICD) placement, mortality at 3 years inc
in those with 3 or more previous HF hospitalizations. Among patients who had 3 o
tation. Adj. HR  adjusted hazard ratio; CI  confidence interval.F at the time of implantation, and their survival wassimilar to what had been demonstrated in the landmark
trials.
Saxon et al. (24) assessed the long-term mortality after
ICD implantation for primary and secondary prevention
during the post-ICD coverage expansion period: 21% died
at 3 years for patients receiving an ICD (n  108,027) and
29% for those receiving CRT-defibrillator (n  77,751).
The overall survival after primary ICD implantation appears to
be shorter among our Medicare population, given that mor-
tality in the Saxon study is likely to have been elevated by
including patients receiving the devices for secondary preven-
tion. The shorter survival after ICD implantation among our
Medicare patients could reflect more severe HF or comorbidi-
ties associated with older age. Compared with primary ICD
recipients in a nationwide ICD registry (25), which includes
patients younger than 66 years of age, our Medicare ICD
recipients had worse HF symptoms by NYHA class.
We attempted to quantify the chronic burden of HF by the
number of previous HF hospitalizations, which has been
shown to be an independent predictor of mortality among HF
patients (26–28). Patients with repeated HF hospitalizations
are more likely to die from nonarrhythmic causes of death such
as pump failure or noncardiac causes (29,30). Moreover,
previous HF hospitalization has been shown to predict early
f Previous HF Hospitalizations
from 27% in patients without previous heart failure (HF) hospitalization to 63%
previous HF hospitalizations, more than one-half died within 2 years of implan-ber o
reased
r moreHF death and lower ICD efficacy in MADIT-II (Multicenter
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ICD and Heart Failure Burden May 28, 2013:2142–50Automatic Defibrillator Implantation Trial II) (31). The de-
cision to implant an ICD in patients with previous HF
hospitalizations should be made cautiously and with appropri-
ately calibrated expectations of HF survival.
To describe the burden of a prolonged exacerbation of
HF, we used the duration from admission to ICD implan-
tation, assuming that prior to implantation patients were
likely undergoing evaluation or treatment either for HF or
for other serious comorbidities. Increasing the number of
days during a HF hospitalization suggests that decompen-
sation is more complicated, more severe, or more refractory
to interventions. Although we were not able to investigate
what happened during the prolonged hospitalization before
the procedure in our study population, our assumption was
supported by the observation that those who received an
elective ICD procedure had shorter times from admission to
implantation (0.3  1 days) than did those who received
ICD during an admission for HF, other cardiac conditions,
or noncardiac conditions (5  4 days). Indications for HF
Figure 2 Kaplan-Meier Cumulative Crude Mortality by the Num
Mortality at 3 years was more than twice as high, from 25% in patients with same
tation. Among patients who had more than 8 hospitalization days before implanta
Mortality at 3 Years After ICD Implantation Among Subgroups CateTable 4 Mortality at 3 Years After ICD Implantation Among Su
Chronic HF Burden
Acute HF Burden 0 Hospital Days From
Admission to Implantation
0 Previous HF Hospitalizations 22 (31,685)
1–2 Previous HF Hospitalizations 35 (7,332)
3 Previous HF Hospitalizations 54 (559)Values are % (n). *The survival times are censored observations.
Abbreviations as in Table 1.admission generally include symptoms at rest, which meet the
definition of class IV HF, for which ICD are generally
considered to be contraindicated. Evidence to support ICD use
among patients with ongoing class IV symptoms is limited, as
these patients were not included in pivotal trials of ICD efficacy
among HF populations (1,3), although the use of ICD with
CRT has been shown to be beneficial in ongoing class IV
patients in the COMPANION (Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure) study
(2). Prevention of SCD would be expected to have less impact
on overall mortality than on preventing death due to HF after
HF decompensation because the major cause of death among
trial patients hospitalized for worsening HF is progressive HF
rather than SCD (32), and HF hospitalization is a major risk
factor for death in ICD recipients (31). Our findings indicate
research is needed on whether ICD implantation during an
admission for HF decompensation will have a survival benefit
due to competing mortality. This may be particularly impor-
tant for patients requiring a prolonged hospitalization given
f Days From Admission to ICD Implantation
plantation to 53% in the patients hospitalized for 8 or more days before implan-
ore than one-half died within 3 years. Abbreviations as in Figure 1.
ed by Acute and Chronic HF Burdensps Categorized by Acute and Chronic HF Burdens
1–7 Hospital Days From
Admission to Implantation
8 Hospital Days From
Admission to Implantation
34 (17,581) 50 (3,697)
50 (4,459) 59 (957)
69 (555) 61 (149)*ber o
-day im
tion, mgorizbgrou
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May 28, 2013:2142–50 ICD and Heart Failure Burdenour finding that length of hospitalization prior to implantation
was associated with shorter survival.
Lastly, the post-implantation mortality among our Medi-
care primary ICD recipients is higher than that of the
patients included in the major primary ICD trials (1,3): 16%
in SCD-HeFT (Sudden Cardiac Death in Heart Failure
Trial) and 22% in MADIT-II (at three-year follow-up).
However, we observed the mortality was similar to that of
the landmark trials (1,3) when ICD were implanted among
Medicare patients who had no previous HF hospitalizations
and who could receive ICD on the admission day (Table 4),
despite the underlying age difference. It is encouraging that
we identified this subpopulation by using the rough proxies
of HF burdens. It is also worth noting that a substantial
proportion of the Medicare ICD recipients were in the “low
HF burden” category at the time of implantation, which
reflects an appropriate selection of Medicare ICD recipients
in the current practice. Nevertheless, future research is
warranted to refine our measures of baseline HF burden to
support clinical decisions on who should receive the device.
Study limitations. Our results should be interpreted in light
of inherent limitations. As mentioned earlier, our analyses did
not include a comparison group of non-ICD recipients and
could not estimate the relative effect of ICD by underlying HF
burdens. The registry and Medicare data were not always in
agreement. For example, 6% of patients who received ICD
with a primary prevention indication were also noted in the
registry to have sustained ventricular tachycardia noted (sug-
Figure 3 Post-Implantation Mortality Among Medicare Populati
Patients who had no HF hospitalization in the year before ICD implantation and re
ICD implantation as those in the major trials did (mortality at 3-year follow-up in pa
in Heart Failure Trial] and MADIT-II [Multicenter Automatic Defibrillator Implantationgesting secondary prevention). We excluded these patients inorder to avoid mixing primary and secondary ICD. A review of
a tertiary care center’s ICD registry found incomplete coding
for indication, further supporting our decision to exclude
patients with discrepant indication data (33).
We linked 64% (n  122,562) of registry records to
MedPAR files. The MedPAR files do not contain claims for
the majority of non-fee-for-service Medicare beneficiaries,
unless those beneficiaries enrolled in a cost-based managed
care plan and the plan elects to have CMS process and pay for
the service provided (34). Given the prevalence of Medicare
beneficiaries under a non-cost-based managed care arrange-
ment, which ranged from 14% to 22% during the study time
frame (34), our matched records represent approximately 79%
of the implantations recorded in the registry that would be for
fee-for-service Medicare beneficiaries. Incomplete linkage may
have also been due to data entry errors or inconsistencies in the
information collection policy between the registry and Medi-
care files on the fields that were used for linkage. For example,
when sex is unknown to Medicare, “female” value is automat-
ically assigned for that claim (35). Also, if arrival to the
emergency department is recorded as the patient’s admission
date in the registry, it will differ from the date recorded in the
claims data. Nevertheless, these errors are likely to be random
and unlikely to compromise the validity of our findings.
Conclusions
Approximately 1 in 3 Medicare primary ICD recipients died
ith Low Burden of HF (n  31,685)
the device on the admission day (47%, n  31,685) had similar mortality after
with low HF burden  22% vs. 16% to 22% in SCD-HeFT [Sudden Cardiac Death
II]). Abbreviations as in Figure 1.ons W
ceived
tients
Trialwithin 3 years of implantation. Medicare patients with a low
m2150 Chen et al. JACC Vol. 61, No. 21, 2013
ICD and Heart Failure Burden May 28, 2013:2142–50cumulative burden of HF had similar mortality to those in the
landmark trials. Further studies are needed to assess effective-
ness of primary ICD implantation among patients with heavy
burdens of HF and other comorbidities to guide clinical
strategies and policy decisions among Medicare beneficiaries.
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APPENDIX
For a description of the final study patients, please see the online version
of this article.
